Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma

Francisco J. Esteva‐Lorenzo, John E. Janik, Robert G. Fenton, Alison Emslie‐Smith, Andrew G. Engel, Dan L. Longo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Interleukin‐2 (IL‐2) has been used successfully in the treatment of some patients with metastatic renal cell carcinoma and melanoma, with a partial response rate of 15%–20%. It produces a well documented spectrum of side effects. Autoimmune diseases have been associated with IL‐2 immunotherapy and the development of autoimmune thyroiditis may correlate with anti‐tumor clinical response. Methods. A patient with metastatic renal cell carcinoma is described who developed a polymyositis‐like myopathy after an autologous tumor vaccine and IL‐2 therapy. Results. The patient had a delayed response for 15 months after developing this previously unreported toxicity. Conclusions. To the authors' knowledge, this represents the first reported case of necrotizing myositis in association with IL‐2 therapy. Subsequent continuous partial response of the advanced malignancy was observed for 15 months. In this case, IL‐2 may have broken tolerance to both normal muscle cells and tumor cells.

Original languageEnglish (US)
Pages (from-to)1219-1223
Number of pages5
JournalCancer
Volume76
Issue number7
DOIs
StatePublished - Jan 1 1995

Fingerprint

Myositis
Renal Cell Carcinoma
Autoimmune Thyroiditis
Active Immunotherapy
Cancer Vaccines
Muscular Diseases
Immunotherapy
Muscle Cells
Autoimmune Diseases
Melanoma
Neoplasms
Therapeutics

Keywords

  • immunotherapy
  • interleukin‐2
  • myositis
  • renal cell cancer
  • tumor vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Esteva‐Lorenzo, F. J., Janik, J. E., Fenton, R. G., Emslie‐Smith, A., Engel, A. G., & Longo, D. L. (1995). Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma. Cancer, 76(7), 1219-1223. https://doi.org/10.1002/1097-0142(19951001)76:7<1219::AID-CNCR2820760719>3.0.CO;2-O

Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma. / Esteva‐Lorenzo, Francisco J.; Janik, John E.; Fenton, Robert G.; Emslie‐Smith, Alison; Engel, Andrew G.; Longo, Dan L.

In: Cancer, Vol. 76, No. 7, 01.01.1995, p. 1219-1223.

Research output: Contribution to journalArticle

Esteva‐Lorenzo, FJ, Janik, JE, Fenton, RG, Emslie‐Smith, A, Engel, AG & Longo, DL 1995, 'Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma', Cancer, vol. 76, no. 7, pp. 1219-1223. https://doi.org/10.1002/1097-0142(19951001)76:7<1219::AID-CNCR2820760719>3.0.CO;2-O
Esteva‐Lorenzo, Francisco J. ; Janik, John E. ; Fenton, Robert G. ; Emslie‐Smith, Alison ; Engel, Andrew G. ; Longo, Dan L. / Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma. In: Cancer. 1995 ; Vol. 76, No. 7. pp. 1219-1223.
@article{d747776ef37c4ac495904df10c6072de,
title = "Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma",
abstract = "Background. Interleukin‐2 (IL‐2) has been used successfully in the treatment of some patients with metastatic renal cell carcinoma and melanoma, with a partial response rate of 15{\%}–20{\%}. It produces a well documented spectrum of side effects. Autoimmune diseases have been associated with IL‐2 immunotherapy and the development of autoimmune thyroiditis may correlate with anti‐tumor clinical response. Methods. A patient with metastatic renal cell carcinoma is described who developed a polymyositis‐like myopathy after an autologous tumor vaccine and IL‐2 therapy. Results. The patient had a delayed response for 15 months after developing this previously unreported toxicity. Conclusions. To the authors' knowledge, this represents the first reported case of necrotizing myositis in association with IL‐2 therapy. Subsequent continuous partial response of the advanced malignancy was observed for 15 months. In this case, IL‐2 may have broken tolerance to both normal muscle cells and tumor cells.",
keywords = "immunotherapy, interleukin‐2, myositis, renal cell cancer, tumor vaccine",
author = "Esteva‐Lorenzo, {Francisco J.} and Janik, {John E.} and Fenton, {Robert G.} and Alison Emslie‐Smith and Engel, {Andrew G.} and Longo, {Dan L.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19951001)76:7<1219::AID-CNCR2820760719>3.0.CO;2-O",
language = "English (US)",
volume = "76",
pages = "1219--1223",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Myositis associated with interleukin‐2 therapy in a patient with metastatic renal cell carcinoma

AU - Esteva‐Lorenzo, Francisco J.

AU - Janik, John E.

AU - Fenton, Robert G.

AU - Emslie‐Smith, Alison

AU - Engel, Andrew G.

AU - Longo, Dan L.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Background. Interleukin‐2 (IL‐2) has been used successfully in the treatment of some patients with metastatic renal cell carcinoma and melanoma, with a partial response rate of 15%–20%. It produces a well documented spectrum of side effects. Autoimmune diseases have been associated with IL‐2 immunotherapy and the development of autoimmune thyroiditis may correlate with anti‐tumor clinical response. Methods. A patient with metastatic renal cell carcinoma is described who developed a polymyositis‐like myopathy after an autologous tumor vaccine and IL‐2 therapy. Results. The patient had a delayed response for 15 months after developing this previously unreported toxicity. Conclusions. To the authors' knowledge, this represents the first reported case of necrotizing myositis in association with IL‐2 therapy. Subsequent continuous partial response of the advanced malignancy was observed for 15 months. In this case, IL‐2 may have broken tolerance to both normal muscle cells and tumor cells.

AB - Background. Interleukin‐2 (IL‐2) has been used successfully in the treatment of some patients with metastatic renal cell carcinoma and melanoma, with a partial response rate of 15%–20%. It produces a well documented spectrum of side effects. Autoimmune diseases have been associated with IL‐2 immunotherapy and the development of autoimmune thyroiditis may correlate with anti‐tumor clinical response. Methods. A patient with metastatic renal cell carcinoma is described who developed a polymyositis‐like myopathy after an autologous tumor vaccine and IL‐2 therapy. Results. The patient had a delayed response for 15 months after developing this previously unreported toxicity. Conclusions. To the authors' knowledge, this represents the first reported case of necrotizing myositis in association with IL‐2 therapy. Subsequent continuous partial response of the advanced malignancy was observed for 15 months. In this case, IL‐2 may have broken tolerance to both normal muscle cells and tumor cells.

KW - immunotherapy

KW - interleukin‐2

KW - myositis

KW - renal cell cancer

KW - tumor vaccine

UR - http://www.scopus.com/inward/record.url?scp=0029087773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029087773&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19951001)76:7<1219::AID-CNCR2820760719>3.0.CO;2-O

DO - 10.1002/1097-0142(19951001)76:7<1219::AID-CNCR2820760719>3.0.CO;2-O

M3 - Article

C2 - 8630901

AN - SCOPUS:0029087773

VL - 76

SP - 1219

EP - 1223

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -